Introduction {#s1}
============

Crohn\'s disease (CD) is characterized by chronic inflammation of different sections of the gastrointestinal tract. The etiology of CD is unknown but it has been hypothesized that the interplay of diverse factors, including the intestinal microbiota, genetic, and immunologic host factors, as well as environmental cues, are responsible for its etiology (Kaser et al., [@B29]). *Escherichia coli* has been shown to occur more often in the gastrointestinal mucosa of patients with CD as compared to non-CD individuals, leading the hypothesis that this microorganism may play a major role in the development of CD (Darfeuille-Michaud et al., [@B14], [@B13]; Schultsz et al., [@B41]; Ryan et al., [@B40]; De la Fuente et al., [@B15]). Furthermore, many of the strains isolated from patients with CD display properties consistent with those exhibited by strains of the adherent-invasive *E. coli* pathotype (AIEC). AIEC strains are able to adhere to and invade epithelial cells, to colonize the intestinal epithelium, and to survive intracellularly in macrophages (Darfeuille-Michaud et al., [@B14]; Boudeau et al., [@B7]; Glasser et al., [@B24]; De la Fuente et al., [@B15]). The virulence factors harbored by AIEC strains differ from those characteristic of other groups of diarrheagenic *E. coli* strains (Darfeuille-Michaud et al., [@B14]; Boudeau et al., [@B7]; Glasser et al., [@B24]; De la Fuente et al., [@B15]).

One of the most studied virulence factors in AIEC strains is *fimH*. This gene encodes an adhesin located at the tip of the Type 1 pili; *FimH* mediates bacterial adhesion to glycosylated and non-glycosylated host receptors, including the matrix-associated type I and IV collagens, laminin, fibronectin, and glycosylated receptors (Sokurenko et al., [@B42]). AIEC that adhere to ileal enterocytes via FimH recognize the carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM-6) receptor, which appears to be overexpressed in the ileal epithelial cells of patients with CD (Barnich et al., [@B3]). In addition, polymorphisms in *fimH* confer a higher ability to adhere to CEACAM-6 (Dreux et al., [@B19]).

Vat-AIEC (Vacuolating autotransporter toxin), a Serine Protease Autotransporters of *Enterobacteriacea* (SPATE) that promotes crossing of the intestinal mucus layer by the LF82 AIEC strain, was recently identified (Gibold et al., [@B23]). SPATEs constitute a superfamily of trypsin-like serine proteases; they are highly prevalent and are generally secreted by enteropathogens (Yen et al., [@B47]; Ruiz-Perez and Nataro, [@B39]). SPATEs have been classified into two groups, class-1 and class-2, based on the amino acidic sequence of their passenger domain and the different functions they perform (Dutta et al., [@B21]; Ruiz-Perez and Nataro, [@B39]). To date, class-1 SPATEs have been reported to display cytotoxic effects on cultured cells and enterotoxin activity on intestinal tissues (Boisen et al., [@B6]; Ruiz-Perez and Nataro, [@B39]). Most class-2 SPATEs studied display mucinase activity and cleave a variety of leukocyte surface glycoproteins (Ruiz-Perez and Nataro, [@B39]). The prevalence and possible role of both class-1 and class-2 SPATEs in AIEC strains has received little attention in the literature.

The aims of the present study were to evaluate the genetic variability of 50 *E. coli* isolates from intestinal biopsies of patients with CD in Chile and Spain and 26 isolates from non-CD subjects, to determine the presence of virulence factors typically found in AIEC strains and in strains associated with CD, and to study *E. coli* strains\' affiliation with the different phylogenetic groups (A, B1, B2, and D). We also compared the presence of class-1 and class-2 SPATEs and polymorphisms in *fimH* gene, between CD and non-CD *E. coli* isolates.

Methods {#s2}
=======

We analyzed 50 *E. coli* strains obtained from patients diagnosed with CD and 26 strains from non-CD patients of which 15 were obtained from subjects who were submitted to colonoscopy for either constipation, anal bleeding, or colon cancer evaluations and had normal colonoscopy results, and 11 were obtained from the feces of normal individuals (Table [1](#T1){ref-type="table"}). Forty nine strains (35 from CD and 14 from non-CD patients) were isolated from biopsies taken from 16 patients who underwent colonoscopy at the Son Espases Reference Hospital (Mallorca, Spain) between August 2011 and March 2012; the microbiome of these patients was previously described using molecular methods (Vidal et al., [@B44]) (Table [1](#T1){ref-type="table"}). The Chilean strains were represented by 27 isolates (15 from CD, 1 from a non-CD patient) obtained from patients who underwent colonoscopy at Clínica Las Condes in Santiago, Chile between July 2010 and January 2011, and 11 strains isolated from feces samples of healthy patients (Table [1](#T1){ref-type="table"}). All strains isolated from patient biopsies were obtained as previously described (De la Fuente et al., [@B15]).

###### 

**Description of the two patients groups, Crohn\'s Disease and Controls, and the number and type of ***Escherichia coli*** isolates**.

  **Patient ID[^a^](#TN1){ref-type="table-fn"}**   ***E. coli* strains isolate**                                **Birth year**   **Origin[^b^](#TN2){ref-type="table-fn"}**   **Year of CD Diagnosis**   **Location[^c^](#TN3){ref-type="table-fn"}**   **Behavior[^d^](#TN4){ref-type="table-fn"}**   **Surgery**           **Medication (at least 3 months before sampling)**   **Clinical status[^e^](#TN5){ref-type="table-fn"}**   **Colonoscopy**
  ------------------------------------------------ ------------------------------------------------------------ ---------------- -------------------------------------------- -------------------------- ---------------------------------------------- ---------------------------------------------- --------------------- ---------------------------------------------------- ----------------------------------------------------- --------------------------------------------------
  **CD PATIENTS**                                                                                                                                                                                                                                                                                                                                                                                                                       
  1C                                               1I06                                                         1975             S                                            2002                       L3                                             B3                                             Ileocolic resection   Immunosuppressive agent                              Clinical activity                                     Anastomotic stenosis with ulcers
  2C                                               2C05, 2I05                                                   1963             S                                            1983                       L3                                             B3                                             Ileal resection       Immunosuppressive agent                              Remission                                             Normal colon and ileum
  [4C]{.ul}                                        4C01, 4I03, 4I01                                             1955             S                                            1990                       L1                                             B2                                             Ileocolic resection   5-aminosalicylates                                   Remission                                             Normal colon, anastomotic stenosis
  [5C]{.ul}                                        5I01, 5C08                                                   1992             S                                            2005                       L3                                             B2                                             Ileocolic             Immunosuppressive agent                              Clinical activity                                     Normal colon anastomotic
  [6C]{.ul}                                        6I01, 6I02, 6I06, 6I07, 6I09, 6I10, 6C03, 6C04, 6C09, 6C10   1958             S                                            2011                       L2                                             B2                                             Ileocolic resection   5-aminosalicylates                                   Remission                                             Normal colon and ileum
  7C                                               7C08, 7C09, 7C02, 7C04, 7C06, 7C07                           1983             S                                            2005                       L3                                             B2                                             NS                    TNF antagononist                                     Remission                                             Inflammatory activity in colon and stenosis
  [9C]{.ul}                                        9C01, 9C02                                                   1976             S                                            1984                       L1                                             B3                                             Ileocolic             TNF antagononist                                     --                                                    Inflammatory activity in ileum
  [10C]{.ul}                                       10C01, 10C05, 10I01, 10I03                                   1949             S                                            1997                       L1                                             B1                                             Ileocolic             5-aminosalicylates                                   Clinical activity                                     Normal colon Anastomotic
  [18C]{.ul}                                       18I08, 18I02, 18C01, 18C02                                   1940             S                                            1940                       L1                                             B3                                             Ileocolic             Immunosuppressive agent                              Clinical activity                                     Normal colon
  24C                                              24C01                                                        1989             S                                            2009                       L1                                             B3                                             Ileocolic resection   Immunosuppressive agent                              Remission                                             Normal colon, anastomotic stenosis
  CD43                                             PT1                                                          1960             CH                                           1988                       L3                                             B2                                             NS                    NM                                                   Clinical activity                                     Ileal and colonic ulcers and colon with stenosis
  CD45                                             JSL                                                          1970             CH                                           2002                       L3                                             B1                                             NS                    Immunosuppressive agent                              Remission                                             Normal colon and ileum
  CD44                                             EII                                                          1985             CH                                           2008                       L2                                             B1                                             NS                    TNF antagononist                                     Clinical activity                                     Normal colon and ileum
  CD37                                             GM                                                           1980             CH                                           2012                       L1                                             B1                                             Ileal resection       Immunosuppressive agent                              Clinical activity                                     Ileal ulcers Anastomotic
  CD19                                             FBC                                                          1982             CH                                           2009                       L3                                             B1                                             NS                    Immunosuppressive agent                              Clinical activity                                     Ileal and rectal ulcers Anastomotic
  CD18                                             CPA                                                          1970             CH                                           ND                         L1                                             B2                                             NS                    --                                                   Clinical activity                                     --
  [CD1]{.ul}                                       CD1-a                                                        1927             CH                                           ND                         L2                                             B1                                             --                    NM                                                   Clinical activity                                     Rectosigmoiditis
  [CD2]{.ul}                                       CD2-a                                                        1966             CH                                           ND                         L2                                             B1                                             --                    NM                                                   No Clinical activity                                  Normal colon and ileum
  [CD6]{.ul}                                       CD6-b, CD6-r                                                 1955             CH                                           ND                         L2                                             B1                                             --                    Immunosuppressive agent                              Clinical activity                                     Diverticulosis Perianal fistula
  CD8                                              CD8-a                                                        1961             CH                                           ND                         L2                                             B2                                             --                                                                         Clinical activity                                     Colon with stenosis Perianal fistula
  [CD9]{.ul}                                       CD9-a                                                        1969             CH                                           ND                         L2                                             B1                                             --                    Anti-inflammatory                                    Clinical activity                                     Colitis in the distal segment
  CD12                                             CD12-a                                                       1984             CH                                           ND                         L2                                             B1                                             --                    --                                                   Clinical activity                                     Edematous colonic lesions
  CD13                                             CD13-a                                                       1989             CH                                           ND                         L3                                             B1                                             --                    --                                                   Clinical activity                                     Colon and ileum active
  [CD14]{.ul}                                      CD14-a                                                       1985             CH                                           ND                         L3                                             B1                                             --                    --                                                   No Clinical activity                                  Closed fistula
  **CONTROL PATIENTS**                                                                                                                                                                                                                                                                                                                                                                                                                  
  14S                                              14I01, 14I02, 14C01, 14C05, 14C06, 14C09                     1952             S                                            Control                                                                                                                                                                                             Constipation                                          Normal colon
  15S                                              15C02                                                        1965             S                                            Control                                                                                                                                                                                             Constipation                                          Normal colon
  16S                                              16C01, 16C02                                                 1945             S                                            Control                                                                                                                                                                                             Hemorrhoid                                            Normal colon
  19S                                              19C01, 19C02                                                                                                               Control                                                                                                                                                                                                                                                   
  22S                                              22C02, 22C05                                                 1938             S                                            Control                                                                                                                                                                                             Hemorrhoid                                            Normal colon
  23S                                              23C01                                                        1961             S                                            Control                                                                                                                                                                                             RCC screening                                         Normal colon
  C7                                               C7-a                                                         1940             CH                                           Control                                                                                                                                                                                                                                                   Normal colon
  D1-D11                                           D1, D2, D3, D4, D5, D6, D7, D8, D9, D10, D11                                  CH                                           Control                                                                                                                                                                                             Stool samples                                         Normal colon

*CD, Crohn\'s Disease*.

*Patient ID underlined indicate that they had E. coli strains whose phenotype corresponded to AIEC*.

*Origin, S-Spain; CH-Chile*.

*Location, L1-Ileal; L2-Colonic; L3-Ileocolonic*.

*Behavior, B1-inflammatory; B2-stricture; B3-penetrant disease*.

*Clinical status, Clinical activity; No Clinical activity; Remission*.

*RCC, rectal colon cancer; NS, no surgery; NM, no medication; ND, no data; TNF, Tumor Necrosis Factor*.

All CD Chilean strains were obtained from ileum biopsies. Almost all Chilean control strains were obtained from stool samples and only one (C7) from an ileum biopsy. The Spanish strains were obtained from colon (C) or ileum (I) biopsies.

Briefly, biopsy samples were suspended in GIBCO® Hank\'s balanced salt solution (HBSS) (Thermo Fisher Scientific; Grand Island, NY, USA) supplemented with 100 μg/ml gentamicin (Sigma-Aldrich; St. Louis, MO, USA), incubated for 1 h at 37°C and then washed with phosphate buffered saline (PBS) and lysed in 100 μl of 1% Triton-X-100/PBS to release intracellular bacteria. The homogenized tissue obtained was plated on MacConkey agar (Oxoid Ltd.; Basingstoke, Hampshire, UK) and incubated for 18 h at 37°C. Determination and confirmation of *E. coli* identification was first performed using biochemical tests and then by PCR. Study participants provided written informed consent before entering the study. The project and informed consent forms were approved by the Institutional Review Board of Clínica Las Condes; Faculty of Medicine, Universidad de Chile; Ethics Committee of the Northern Metropolitan Health Service, Santiago, Chile; and the Balearic Islands\' Ethical Committee, Spain. All records and information was kept confidential and all identifiers were removed prior to analysis.

*E. coli* K-12, NRG857c (Nash et al., [@B36]), K-12, HS (DuPont et al., [@B20]; Levine et al., [@B32]), and HM605 (Clarke et al., [@B10]) were included as reference strains. All strains were cultured in Luria-Bertani (LB) agar or LB broth (BD Diagnostics; Sparks Glencoe, MD, USA) at 37°C for 18 h.

PFGE was performed according to the protocol described on the PulseNet website of the U.S. Centers for Disease Control & Prevention, using *XbaI* and *SpeI* restriction enzymes (CDC; <http://www.cdc.gov/pulsenet/PDF/ecoli-shigella-salmonella-pfge-protocol-508c.pdf>). The genetic variability of the CD *E. coli* strains including reference strains HS, reference AIEC strains NRG857c and HM605 (kindly provided by A. Torres and I. Henderson, respectively) and non-CD strains was analyzed by pulse-field gel electrophoresis (PFGE). A *Salmonella enterica* serotype Braenderup (H9812 strain) was used as a gel loading control. PFGE patterns were analyzed with the GEL COMPAR II software (Applied Maths), using the Dice similarity coefficient with a 0.9 % tolerance in band position. Phylogenetic affiliation (A, B1, B2, or D groups) was performed using a previously described method (Clermont et al., [@B11]). Virulence genotyping was determined by amplifying the following virulence-associated genes commonly present in extraintestinal pathogenic *E. coli* (ExPEC): *cnf1, hlyA, cdtB, neuC, ibeA, papC, sfa/focDE, afa/draBC, fimH*, and *fimAvMT78* (Martinez-Medina et al., [@B35]), as well as other pathogenicity-associated factors, such as the adhesin synthesis gene (*aufA*), toxins (*ratA, cvaC*), iron uptake (*irp2, fhuD, and chuA*), and Peyer\'s patch survival (*gipA*). PCR primers used for gene amplification are detailed in Table [2](#T2){ref-type="table"} and PCR amplifications were performed under standard conditions, as previously described (Martinez-Medina et al., [@B35]).

###### 

**Primers used to PCR analyses for adhesins, iron uptake proteins, toxins, ***E. coli*** phylogenetics groups, SPATEs, and others virulence factors**.

  **Primer sequences (5^′^--3^′^)**        **Target sequences**                                             **References**
  ---------------------------------------- ---------------------------------------------------------------- -----------------------------
  **ADHESIN**                                                                                               
  afaBC-F: GCTGGGCAGCAAACTGATAACTCTC       Afimbrial adhesin                                                Le Bouguenec et al., [@B31]
  afaBC-R: CATCAAGCTGTTTGTTCGTCCGCCG                                                                        
  aufA-F: TTGGTGGGGCGGATACTGAC             Putative fimbrial-like protein                                   This study
  aufA-R: TGTATAAGCGGCGGTGGAGG                                                                              
  fimA~v\ MT78~-F: TCTGGCTGATACTACACC      Variant form of the type 1 major fimbrial subunit                Marc and Dho-Moulin, [@B33]
  fimA~v\ MT78~-R: ACTTTAGGATGAGTACTG                                                                       
  fimH-F: GATCTTTCGACGCAAATC               Adhesin of type 1 fimbriae                                       Arne et al., [@B1]
  fimH-R: CGAGCAGAAACATCGCAG                                                                                
  papC-F: GACGGCTGTACTGCAGGGTGTGGCG        Pyelonephritis associated pili                                   Le Bouguenec et al., [@B31]
  papC-R: ATATCCTTTCTGCAGGGATGCAATA                                                                         
  sfa/focDE-F: CTCCGGAGAACTGGGTGCATCTTAC   S-fimbrial and *F1C fimbriae* dhesion                            Le Bouguenec et al., [@B31]
  sfa/focDE-R:CGGAGGAGTAATTACAAACCTGGCA                                                                     
  **IRON ACQUISITION**                                                                                      
  chuA-F:TATGATGGTCAGCGTTATCGAC            Outer membrane hemin receptor                                    This study
  chuA-R: CATAGCCAGGTTGTTTGCTGTA                                                                            
  fhuD-F: AACCTTGAACTGCTGACCGAAAT          Component of the ferric hydroxamate uptake (Fhu) system          This study
  fhuD-R: GTACTGCCCCAGAAGTTGGTTTC                                                                           
  irp2-F: CGCAGAATCGCTGTTAGCAC             Iron regulatory protein 2                                        This study
  irp2-R: TGGTAGCGATCTTCAGGGGA                                                                              
  **TOXINS**                                                                                                
  cdtB-F: GAAAGTAAATGGAATATAAATGTCCG       Cytolethal distending toxin, subunit B                           Johnson and Stell, [@B28]
  cdtB-R: AAATCACCAAGAATCATCCAGTTA                                                                          
  cnfI-F: AAGATGGAGTTTCCTATGCAGGAG         Cytotoxic necrotizing factor 1                                   Yamamoto et al., [@B46]
  cnfI-R: CATTCAGAGTCCTGCCCTCATTATT                                                                         
  cvaC-F: CACACACAAACGGGAGCTGTT            Gene codes for the structural gene for colicin V α-Hemolysin     Johnson and Stell, [@B28]
  cvaC-R: CTTCCCGCAGCATAGTTCCAT                                                                             
  hlyA-F: AACAAGGATAAGCACTGTTCTGGCT        Alfa hemolysin                                                   Yamamoto et al., [@B46]
  hlyA-R: ACCATATAAGCGGTCATTCCCGTCA                                                                         
  ratA-F: CCGTCATTTTCGCCGCACCT             Ribosome association toxin                                       This study
  ratA-R: ACCCACAGCCAGTCGCAGAT                                                                              
  **OTHERS VIRULENCE GENES**                                                                                
  ibeA-F: AGGCAGGTGTGCGCCGCGTAC            Invasion of brain endothelial (IbeA) protein (invasin)           Johnson and Stell, [@B28]
  ibeA-R: TGGTGCTCCGGCAAACCATGC                                                                             
  gipA-F: TTCCCCTCCAGCAGTCGTTG             Peyer\'s patch-specific factor                                   This study
  gipA-R: GAACATCCAGCGGCGACTTG                                                                              
  neuCK1-F: AGGTGAAAAGCCTGGTAGTGTG         K1 capsular polysaccharide                                       Watt et al., [@B45]
  neuCK1-R: GGTGGTACATTCCGGGATGTC                                                                           
  pduC-F: GTTGCCGTTGCTCGCTATGC             Coenzyme B12-dependent 1,2-propanediol catabolism                This study
  pduC-R: ACTGCACGGATGCCTGATGG                                                                              
  ***E. coli*** **PHYLOGENETIC GROUPS**                                                                     
  chuA.1: GACGAACCAACGGTCAGGAT             Outer membrane hemin receptor                                    Clermont et al., [@B11]
  chuA.2: TGCCGCCAGTACCAAAGACA                                                                              
  yjaA.1: TGAAGTGTCAGGAGACGCTG             Coding for protein of unknown function                           Clermont et al., [@B11]
  yjaA.2: ATGGAGAATGCGTTCCTCAAC                                                                             
  tspE4C2.1: GAGTAATGTCGGGGCATTCA          Tsp encodes for a putative DNAfragment (TSPE4.C2) in *E. coli*   Clermont et al., [@B11]
  tspE4C2.2: CGCGCCAACAAAGTATTACG                                                                           
  **SPATEs CLASS-1 (Cl-1)**                                                                                 
  Sat1: TCAGAAGCTCAGCGAATCATTG             Secreted autotransporter toxin                                   Boisen et al., [@B6]
  Sat2: CATTATCACCAGTAAAACGCACC                                                                             
  sigA 1: CCGACTTCTCACTTTCTCCCG            Exported serine protease SigA                                    Boisen et al., [@B6]
  sigA 2: CCATCCAGCTGCATAGTGTTTG                                                                            
  pet 1: GGCACAGAAT AAAGGGGTGTTT           Plasmid-encoded toxin                                            Boisen et al., [@B6]
  pet 2: CCTCTTGTTTCCACGACATAC                                                                              
  espP 1: GTCCATGCAGGGACATGCCA             Extracellular serine protease                                    Boisen et al., [@B6]
  espP 2: TCACATCAGCACCGTTCTCTAT                                                                            
  espC 1: AGTGCAGTGCAGAAAGCAGTT            Plasmid (pO157)-encoded)                                         Boisen et al., [@B6]
  espC 2: AGTTTTCCTGTTGCTGTATGCC           EPEC secreted protein C                                          
  **SPATEs CLASS-2(Cl-2)**                                                                                  
  pic 1: ACTGGATCTTAAGGCTCAGGAT            Protease involved in intestinal colonization                     Boisen et al., [@B6]
  pic 2: GACTTAATGTCACTGTTCAGCG                                                                             
  sepA 1: GCAGTGGAAATATGATGCGGC            *Shigella* extracellular protein A                               Boisen et al., [@B6]
  sepA 2: TGTTCAGATCGGAGAAGAACG                                                                             
  tsh 1: CCGTACACAAATACGACGG               Temperature-sensitive hemagglutinin                              Boisen et al., [@B6]
  tsh 2: GGATGCCCCTGCAGCGT                                                                                  
  vat 1: AACGGTTGGTGGCAACAATCC             Vacuolating autotransporter toxin                                Boisen et al., [@B6]
  vat 2: AGCCCTGTAGAATGGCGAGTA                                                                              
  eatA1:CAGGAGTGGGAACATTAAGTCA             Autotransporter protein of enterotoxigenic *E. coli*.            Boisen et al., [@B6]
  eatA 2: CGTACGCCTTTGATTTCAGGAT                                                                            
  EaaA1: GAAGACGAACTGGTTTACGGTG            EaaA from Prophage P-EibA                                        This study
  EaaA 2: GTGGCATTATCAGCATCAATATC                                                                           
  EcNA114 1: ACTCAGACATGGAAAGGCGGC         EcNA114-C2sp From UPEC NA144                                     This study
  EcNA114 2: CTCCAGTGATGATCCCACCC                                                                           

Class-1 (*sat, pet, sigA, espP, espC*) and class-2 (*sepA, eatA, vat, tsh, pic, eaaA, ecNA144*) SPATEs (Dutta et al., [@B21]; Ruiz-Perez and Nataro, [@B39]) were PCR detected using previously described primers (Boisen et al., [@B6]), as well as others described in Table [2](#T2){ref-type="table"}.

AIEC strains are characterized by their ability to: (i) adhere to epithelial cells, (ii) invade epithelial cells, and (iii) survive intracellularly in macrophages (Darfeuille-Michaud et al., [@B14]; Boudeau et al., [@B7]; Glasser et al., [@B24]; De la Fuente et al., [@B15]). Analysis of adhesion and invasion in epithelial cells properties was performed as previously described (Boudeau et al., [@B7]). Briefly, duplicate 24-well plates containing confluent monolayers of Caco-2 cells were infected at a 10:1 multiplicity of infection (MOI) for 30 min at 37°C in a 5% CO~2~ atmosphere. The cell monolayers were washed three times with PBS, and the adherent bacteria were harvested by lysis with 0.1% Triton X-100, serially diluted and plated on LB agar plates. Results are expressed as the percent of adherent bacteria with respect to the total bacteria present after infection (planktonic bacteria plus adherent bacteria). For the invasion assay, the cell monolayer, previously infected for 30 min, was washed three times and then incubated for 3 h with medium containing 100 μg of amikacin/ml. After 3 h, the cell monolayer was washed three times with PBS and bacteria were harvested by lysis with 0.1% Triton X-100. Bacteria were considered able to survive when the ratio between the number of intracellular bacteria and initial inoculums was ≥ 0.1%.

Analysis of survival and replication of the strains in urine RAW 264.7 macrophages were done according to Glasser et al. ([@B24]) with some modifications. Confluent monolayers of murine RAW 264.7 macrophages were infected at a 10:1 MOI for 2 h and incubated at 37°C in a 5% CO~2~ atmosphere. After 2 h of incubation, the cell monolayer was washed three times with PBS, and then incubated for 1 h with medium containing 100 μg of amikacin/ml. Three and 24 h post-infection, the cell monolayer was washed with PBS and bacteria were harvested by lysis with 0.1% Triton X-100. The number of CFU/ml recovered was determined. Bacteria were considered invasive when the ratio between the number of intracellular bacteria and initial inoculum was ≥0.1%, and considered able to survive when the number of intracellular bacteria recovered at 24 h was comparable to that recovered at 3 h post infection (100%) or similar to those obtained for reference AIEC strains. In addition, *E. coli* strain isolated form CD that was recovered with a similar or higher ratio than NRG857c and HM605, was considered able to replicate intracellularly. All assays were performed in triplicate.

Amplification of *fimH* was conducted with fimH-F and fimH-R primers (Table [2](#T2){ref-type="table"}) using High-Fidelity DNA polymerase (Thermo Fisher Scientific; Waltham, MA, USA). PCR products were purified, following the manufacturer\'s instructions (EZNA gel extraction kit, Omega Bio-Tek; Norcross, GA, USA), cloned into pGEM-T Easy vector (Promega; Madison, WI, USA), and then sequenced by MACROGEN (Rockville, MD, USA). The *fimH* nucleotide sequences were translated to protein sequences and compared to orthologous protein sequences. Phylogenetic reconstruction based on FimH protein sequences was obtained by Kimura 2-parameter method and a phylogenetic tree was plotted using the nearest-neighbor joining method in MEGA software, version 6.0.

We considered adhesins, iron-transporters, and toxins along with other virulence factors as potential biomarker candidates for CD or AIEC strains phenotype. The association between these candidates and Crohn\'s disease was statistically estimated using hypothesis testing. We decided to test for biomarkers using by two tests: the Chi-squared independence and proportions comparison, and Odds Ratio (OR) computations. Estimations and computations were performed at VassarStats statistical computation website (<http://vassarstats.net/index.html>).

Results {#s3}
=======

Genomic types among *E. coli* strains
-------------------------------------

A set of 76 strains obtained from 24 patients with CD and 18 non-CD patients were included in the present study (Table [1](#T1){ref-type="table"}). Seventy one strains were initially selected and analyzed by PFGE using *XbaI* and *SpeI* restriction enzymes. Two main groups (clusters 1 and 2) composed of 70 strains were separated with similarity values \>60%. One Chilean strain (CPA) was separated from the other *E. coli* strains studied (Figure [1](#F1){ref-type="fig"}). The larger cluster (Cluster 1, 66/70) is subdivided into two smaller groups, cluster 1.1, which contains most of the CD and non-CD strains and cluster 1.2, which is composed of 17 CD strains and 2 clonal non-CD strains (16C02 and 16C01). AIEC reference strains NRG857c and HM605 were placed in two branches of cluster 1.1.2.2.1. The smaller cluster (Cluster 2, 4/70), is composed of three non-CD strains (D11, D8 and C7-a) and one CD strain (CD12-a).

![**Clonal relationship between ***Escherichia coli*** strains obtained from intestinal biopsies from patients with CD, biopsies or stool from non-CD patients and reference strains**. The dendrogram based on pulsed-field gel electrophoresis (PFGE) using the *XbaI* and *SpeI* enzymes, allowed the identification of two main groups. Crosses indicate strains isolated from Crohn\'s disease patients. Clonal related strains are gray shadows highlighted. The reference strains used (Reference) were (^\*^) HM605 (AIEC), (^\*\*^) NRG857c (AIEC) and (^\*\*\*^) HS (commensal *E. coli*).](fmicb-08-00639-g0001){#F1}

In almost all strains, pattern diversity was remarkable, and non-clonal varieties (i.e., identical profiles) were observed, with the exception of PFGE pattern types of strains isolates within a single patient, which were clonal or closely related (i.e., 14C05, 14I01, 14I02, 14C01, 14C06, and 14C09 isolated from patient 14S; 6I01, 6I06, 6I07, 6C03, 6C04, 6C10, 6I02, and 6I09 isolated from patient 6C; 10C01 and 10C05 isolated from patient 10C; 18I08, 18C01 and 18C02 isolated from patient 18C; 4C01, 4I03 isolated from patient 4C; 19C02, 19C01 isolated from patient 19S; 16C02 and 16C01 isolated from patient 16S; 10I01 and 10I03 isolated from patient 10C; 7C08 and 7C09; 7C02,7C06,7C07, 7C04 isolated from patient 7C; 22C05 and 22C02 isolated from patient 22S; 2C05 and 2I05 isolated from patient 2C). From each group of clonal strains, a single strain was selected for further analysis, resulting in 32 non-clonal CD-strains and 18 non-CD (commensal *E. coli*) strains. Of these 32 strains isolated from patients with CD, 13 were of an AIEC phenotype (Table [3](#T3){ref-type="table"}). There was no significant difference (*p* \> 0.05) in the prevalence of AIECs between Spanish (41.1%, 7/17) and Chilean strains (40%, 6/15).

###### 

**Phylogenetic groups and virulence genes detected by PCR in ***Escherichia coli*** strains isolated from Crohn\'s disease and control patients (non-CD strains)**.

  **Strains**                                **phylogroup**   ***flmH***   ***aufA***   ***papC***   ***fimAv***   ***afaBC***   ***Sfa/focDE***   ***fhuD***   ***chuA***   ***irp2***   ***ratA***   ***cvaC***   ***hlyA***   ***cnfl***   ***cdtB***   ***pduC***   ***neuCk1***   ***gipA***   ***ibeA***   **Cl-1**   **Cl-2**   **AlEC phenotype**   **Surgery**   **Immunosupressive agent**   **Medication IFN-γ**   **Clinical activity**   **Remission**
  ------------------------------------------ ---------------- ------------ ------------ ------------ ------------- ------------- ----------------- ------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------ -------------- ------------ ------------ ---------- ---------- -------------------- ------------- ---------------------------- ---------------------- ----------------------- ---------------
  **SPANISH STRAINS**                                                                                                                                                                                                                                                                                                                                                                                                                                 
  1I06                                       D                \+           --           --           \+            --            --                \+           \+           \+           --           --           --           --           --           --           --             --           --           --         --         --                   \+            \+                           --                     \+                      --
  2C05                                       B2               \+           --           --           --            --            --                \+           \+           --           --           --           --           --           --           --           \+             --           --           --         --         --                   \+            \+                           --                     --                      \+
  4C01                                       B2               \+           --           --           --            --            --                \+           \+           \+           --           --           --           --           --           \+           --             --           --           \+         \+         \+                   \+            \+                           --                     --                      \+
  4I01                                       B2               \+           --           --           --            --            --                \+           \+           \+           --           --           --           --           --           \+           --             --           --           \+         \+         \+                   \+            \+                           --                     --                      \+
  5C08                                       B1               \+           --           --           --            --            --                \+           --           \+           --           \+           --           --           --           --           \+             --           --           --         --         --                   \+            \+                           --                     \+                      --
  5I01                                       B2               \+           \+           --           --            --            --                \+           \+           \+           --           \+           --           --           --           \+           \+             --           --           --         --         \+                   \+            \+                           --                     \+                      --
  6I01                                       B2               \+           --           --           \+            --            --                \+           \+           \+           \+           --           --           --           --           \+           \+             --           --           \+         --         --                   \+            \+                           --                     --                      \+
  6I09                                       D                \+           --           --           --            --            --                \+           \+           \+           --           --           --           --           --           \+           \+             \+           --           --         --         \+                   \+            \+                           --                     --                      \+
  6I10                                       D                \+           \+           \+           --            --            \+                \+           \+           \+           \+           --           \+           \+           --           --           \+             \+           --           \+         \+         --                   \+            \+                           --                     --                      \+
  7C02                                       D                \+           --           --           --            --            --                \+           \+           \+           --           \+           --           --           --           --           --             --           --           \+         \+         --                   --            --                           \+                     --                      \+
  7C08                                       D                \+           \+           --           --            --            --                \+           \+           \+           --           \+           \+           --           --           \+           \+             --           --           \+         \+         --                   \+            --                           \+                     --                      \+
  9C01                                       B2               \+           --           --           --            --            --                \+           \+           \+           --           --           --           --           --           --           --             --           --           \+         \+         \+                   \+            --                           \+                     \+                      --
  10C01                                      D                \+           --           --           --            --            --                \+           \+           \+           --           --           --           --           --           \+           \+             --           --           \+         --         --                   \+            \+                           --                     \+                      --
  10I01                                      D                \+           \+           --           --            --            --                \+           \+           \+           \+           --           --           --           --           \+           \+             --           --           --         --         \+                   \+            \+                           --                     \+                      --
  18I02                                      B2               \+           --           --           --            --            --                \+           \+           \+           --           \+           --           --           --           \+           --             \+           \+           --         \+         --                   \+            \+                           --                     \+                      --
  18I08                                      B2               \+           \+           --           --            --            --                \+           \+           \+           \+           --           --           --           --           \+           \+             \+           \+           --         \+         \+                   \+            \+                           --                     \+                      --
  24C01                                      B2               \+           --           \+           --            --            --                \+           \+           \+           --           --           --           --           --           --           --             --           --           \+         \+         --                   \+            \+                           --                     --                      \+
  **CHILEAN STRAINS**                                                                                                                                                                                                                                                                                                                                                                                                                                 
  CD1--a                                     D                \+           --           \+           --            --            --                \+           \+           --           \+           --           --           --           --           \+           --             --           --           \+         --         \+                   NI            --                           --                     \+                      --
  CD2--a                                     D                \+           --           \+           --            --            --                \+           \+           --           \+           --           --           --           --           \+           --             --           --           \+         --         \+                   NI            --                           --                     --                      \+
  CD6--b                                     B2               \+           --           \+           --            \+            --                \+           \+           \+           --           --           --           --           --           --           --             --           --           \+         \+         \+                   NI            \+                           --                     \+                      --
  CD6--r                                     D                \+           --           --           --            --            --                \+           \+           --           --           \+           --           --           --           --           --             --           --           --         \+         \+                   NI            \+                           --                     \+                      --
  CD8--a                                     A                \+           --           --           --            --            --                \+           --           \+           --           --           --           --           --           --           --             --           --           --         --         --                   NI            NI                           NI                     \+                      --
  CD9--a                                     A                \+           --           --           --            --            --                \+           --           --           --           --           --           --           --           --           --             --           --           \+         --         \+                   NI            \+                           --                     \+                      --
  CD12--a                                    A                \+           --           --           --            --            --                \+           --           --           --           \+           --           --           --           --           --             --           --           --         --         --                   NI            NI                           NI                     \+                      --
  CD13--a                                    A                \+           --           --           --            --            --                \+           --           \+           --           \+           --           --           --           --           --             --           --           --         --         --                   NI            NI                           NI                     \+                      --
  CD14--a                                    B2               \+           --           --           --            --            --                \+           \+           \+           --           --           --           --           --           --           --             --           --           \+         \+         \+                   NI            NI                           NI                     --                      \+
  JSL                                        D                \+           --           --           --            --            --                \+           \+           \+           \+           --           --           --           --           \+           --             --           --           --         --         --                   --            \+                           --                     --                      \+
  E11                                        D                \+           --           --           \+            --            --                \+           \+           --           \+           --           --           --           --           \+           --             --           --           --         --         --                   --            --                           \+                     \+                      --
  GM                                         D                --           \+           --           --            --            --                \+           \+           \+           \+           --           --           --           --           --           --             --           --           --         \+         --                   \+            \+                           --                     \+                      --
  PT1                                        B2               \+           --           --           --            --            --                \+           \+           \+           --           --           --           --           --           \+           \+             --           \+           \+         \+         --                   --            --                           --                     \+                      --
  FBC                                        D                \+           --           \+           --            --            --                \+           \+           \+           \+           --           --           --           --           \+           --             --           --           \+         --         --                   --            \+                           --                     \+                      --
  CPA                                        D                \+           --           --           --            --            --                \+           \+           \+           --           --           --           --           --           --           --             --           --           \+         --         --                   --            NI                           NI                     \+                      --
  **AIEC TYPE**                                                                                                                                                                                                                                                                                                                                                                                                                                       
  HM605                                      B2               \+           \+           \+           --            --            --                \+           \+           \+           \+           \+           --           --           --           --           \+             --           --           --         \+         \+                   NI            NI                           NI                     NI                      NI
  NRG857c                                    B2               \+           \+           --           \+            --            --                \+           \+           \+           \+           \+           --           --           --           \+           --             \+           \+           --         \+         \+                   NI            NI                           NI                     NI                      NI
  **NON--CD STRAINS**                                                                                                                                                                                                                                                                                                                                                                                                                                 
  D1[^\*^](#TN6){ref-type="table-fn"}        B1               \+           --           --           --            --            --                \+           --           --           --           \+           --           --           --           --           --             --           --           --         --         --                   --            --                           --                     --                      --
  D2[^\*^](#TN6){ref-type="table-fn"}        B1               \+           --           --           --            --            --                \+           --           --           --           --           --           --           --           \+           --             --           --           --         --         --                   --            --                           --                     --                      --
  D3[^\*^](#TN6){ref-type="table-fn"}        B2               --           --           --           --            --            --                \+           \+           \+           --           --           --           --           --           --           --             --           --           \+         \+         --                   --            --                           --                     --                      --
  D4[^\*^](#TN6){ref-type="table-fn"}        B1               --           --           --           --            --            --                \+           --           \+           --           --           --           --           --           --           --             \+           --           --         --         --                   --            --                           --                     --                      --
  D5[^\*^](#TN6){ref-type="table-fn"}        B2               \+           --           --           \+            --            --                \+           \+           \+           --           --           --           --           --           --           --             --           --           \+         \+         --                   --            --                           --                     --                      --
  D6[^\*^](#TN6){ref-type="table-fn"}        D                \+           \+           \+           \+            \+            --                \+           \+           \+           --           --           --           --           --           --           \+             --           --           \+         --         --                   --            --                           --                     --                      --
  D7[^\*^](#TN6){ref-type="table-fn"}        A                \+           --           --           --            --            --                \+           --           \+           --           --           --           --           --           --           \+             \+           --           \+         --         --                   --            --                           --                     --                      --
  D8[^\*^](#TN6){ref-type="table-fn"}        A                \+           --           --           --            \+            --                \+           --           \+           --           \+           --           --           --           --           \+             --           --           \+         --         --                   --            --                           --                     --                      --
  D9[^\*^](#TN6){ref-type="table-fn"}        A                \+           --           --           --            --            --                \+           --           \+           --           \+           --           --           --           --           \+             --           --           \+         --         --                   --            --                           --                     --                      --
  D10[^\*^](#TN6){ref-type="table-fn"}       D                \+           \+           \+           --            --            --                \+           \+           \+           --           --           --           --           --           --           \+             --           --           \+         --         --                   --            --                           --                     --                      --
  D11[^\*^](#TN6){ref-type="table-fn"}       A                \+           --           --           \+            --            --                \+           --           \+           --           --           \+           --           --           --           --             --           --           \+         \+         --                   --            --                           --                     --                      --
  C7--a[^\*\*^](#TN7){ref-type="table-fn"}   A                \+           --           \+           --            --            --                \+           --           --           --           --           --           --           --           --           --             --           --           \+         --         --                   --            --                           --                     --                      --
  14C05[^\*\*^](#TN7){ref-type="table-fn"}   B1               \+           --           \+           \+            --            --                \+           --           --           --           \+           --           --           --           --           --             --           --           --         --         --                   --            --                           --                     --                      --
  15C02[^\*\*^](#TN7){ref-type="table-fn"}   D                \+           --           --           \+            --            --                \+           --           --           --           --           --           --           --           \+           --             \+           \+           --         --         --                   --            --                           --                     --                      --
  16C02[^\*\*^](#TN7){ref-type="table-fn"}   A                \+           \+           --           --            \+            --                \+           \+           \+           \+           --           --           --           --           \+           \+             \+           \+           --         \+         --                   --            --                           --                     --                      --
  19C01[^\*\*^](#TN7){ref-type="table-fn"}   B2               \+           \+           --           \+            --            --                \+           \+           \+           --           \+           --           --           --           \+           \+             --           --           \+         \+         --                   --            --                           --                     --                      --
  22C05[^\*\*^](#TN7){ref-type="table-fn"}   B2               \+           \+           --           --            \+            --                \+           \+           --           --           --           \+           --           --           --           \+             --           --           --         --         --                   --            --                           --                     --                      --
  23C01[^\*\*^](#TN7){ref-type="table-fn"}   A                --           --           --           --            --            --                \+           --           --           --           --           --           --           --           \+           --             --           --           --         --         --                   --            --                           --                     --                      --
  **COMMENSAL TYPE**                                                                                                                                                                                                                                                                                                                                                                                                                                  
  HS                                         A                \+           --           --           --            --            --                \+           --           --           --           --           --           --           --           --           --             --           --           --         --         --                   --            --                           --                     --                      --

*NI, without information*.

*Non-CD strains from Chile*.

*Non-CD strains from Spain*.

The dendrogram (Figure [1](#F1){ref-type="fig"}) revealed that even strain from the same geographic origin appeared intermixed as they did not group according to their origin. In addition, most *E. coli* clinical isolates-derived from patients with CD were associated with B2 and D genomic types (accounting for 84% of all strains, 27/32, *p* \< 0.05). A very small percentage of CD strains were clustered within the genomic types B1 (3.1%, 1/32) and A (12.5%, 4/32). Furthermore, AIEC strains were also associated with the genomic groups B2 and D (92.3%, 12/13, *p* \< 0.05), with the exception of AIEC strain CD9-a, which was associated with genomic group A. A significantly lower number of strains was isolated from group A in AIEC compared to non-AIEC strains (*p* \< 0.05). On the other hand, isolates from non-CD patients were similarly distributed among these four main genomic types (38.8%, 7/18 in A; 22.2%, 4/18 in B1; 22.2%, 4/18 in B2; and 16.6%, 3/18 in D).

Occurrence of virulence factors
-------------------------------

Similarly, the distribution of virulence factors was diverse among the 32 CD strains studied. *fhuD* was present in all strains, including non-CD and reference strains, while *cdtB* was absent in all strains. *fimH* was present in almost all CD (96.8%, 31/32) and non-CD strains (83.3%, 15/18) studied. The most frequently detected factors were those coding for proteins associated with iron uptake, such as *fhuD* (32/32), *irp2* (25/32), and *chuA* (27/32). These factors were significantly more common in CD strains (69%) than in non-CD strains 33%) (OR: 4.4, 95% CI, *p* \< 0.05; Table [4](#T4){ref-type="table"}). Moreover, the most significant individual biomarker of CD strains was *chuA* (OR=8.5, 95% CI, *p* \< 0.001). These results demonstrate that the presence of 3 iron transporters, and in particular chuA, is significantly associated with CD strains (Table [4](#T4){ref-type="table"}). Furthermore, *chuA* is significantly associated with AIEC strains compared to non-AIEC strains (OR: 8.2, 95% CI, 0.95--69.74, *p* \< 0.05). Nevertheless, in the case of adhesins, there was no observed association with CD. The adhesin gene *fimAv* was found to be negatively associated with CD (OR: 0.2, 95%CI: 0.04--0.96, *p* \< 0.05). Toxin analysis showed that the most frequent toxin gene detected was *ratA*, which was present in 31.2% (10/32) of strains, and also allowed discrimination between CD strains (OR:7.7, 95%CI: 0.89--66.39, *p*-value \> 0.05). The other toxin genes were rare in CD strains (Table [3](#T3){ref-type="table"}), as were *cdtB* (0/32) and *cnfI* (1/32). The frequency of other virulence factors was as follows: *ibeA*: 9.3% (3/32), *gipA*: 12.5% (4/32), *pduC*; 50% (16/32), and *neuC*: 34% (11/32). *pduC* (propanediol catabolism) occurred in approximately 50% of the CD strains and was not significantly associated with CD (OR:2.6; 95%CI: 0.75--9.00, *p* \> 0.1).

###### 

*****Escherichia coli*** virulence genes in strains isolated from CD and non-CD and their association with Crohn\'s**.

  **Virulence factors**                   **Odds Ratio (OR)**    ***P*-value**   **CD Association**
  --------------------------------------- ---------------------- --------------- ----------------------
  **ADHESINS**                                                                   
  *fimH*                                  6.2 (0.59--64.72)      0.127           NS
  *fimAv*                                 0.2 (0.04--0.96)       0.043^\*^       Negative association
  *aufA*                                  0.6 (0.15--2.33)       0.345           NS
  *papC*                                  0.6 (0.15--2.33)       0.345           NS
  *sfa/focDE*                             --                     --              --
  *afaBC*                                 0.1 (0.0115--1.1043)   0.050           NS
  **IRON TRANSPORTERS**                                                          
  *fhuD*                                  --                     --              --
  *chuA*                                  8.5 (2.21--32.56)      0.001^\*\*^     Positive association
  *irp2*                                  2.3 (0.64--8.05)       0.168           NS
  three transporters *fhuD, chuA, irp2*   4.4 (1.28--15.09)      0.016^\*^       Positive association
  **TOXINS**                                                                     
  *ratA*                                  7.7 (0.89--66.39)      0.034^\*^       Positive association
  *cvaC*                                  0.9 (0.23--3.19)       0.541           NS
  *hlyA*                                  0.5 (0.06--4.15)       0.456           NS
  *cnfl*                                  --                     --              --
  *cdtB*                                  --                     --              --
  **OTHER VIRULENCE FACTORS**                                                    
  *pduC*                                  2.6 (0.75--9.00)       0.108           NS
  *neuC*                                  0.6 (0.20--2.13)       0.342           NS
  *gipA*                                  0.5 (0.10--2.30)       0.303           NS
  *ibeA*                                  0.8 (0.1--5.48)        0.599           NS
  **SPATEs**                                                                     
  CL-1                                    0.9 (0.28--2.89)       0.552           NS
  CL-2                                    2.0 (0.58--7.02)       0.209           NS

*Association between virulence factors and CD. Odds ratio measures how much the affected/non-affected rate increases with the factor. P-values, computed by Fisher Exact Probability Test (one-tailed), give the statistical significance of such effects. Last column indicates association S, Significant (significant (\<0.05^\*^); very significant (\<0.01)^\*\*^); NS, Non Significant for null (non-significant) association. Notation:-- for not a number*.

At least one class-1 or class-2 SPATE gene was found in 66% (21/32) of the CD strains and genes from both classes of SPATEs were present in 31% (10/32) of CD strains (Table [3](#T3){ref-type="table"}). In AIEC strains this prevalence was 76% (10/13) and 38% (5/13), respectively. Class-1 SPATE genes were detected in 53% (17/32) of CD strains and class-2 SPATEs were detected in 44% (14/32) of CD strains. 62% (8/13) of AIEC strains contained class-1 SPATEs and 54% (7/13) contained class-2 SPATES. The presence of class-1 and class-2 SPATE genes was not significantly associated with CD or AIEC strains. On the other hand, 61%, (11/18) of non-CD strains harbored genes encoding at least one, class-1 or class-2 SPATEs, and 22% (4/18) more than one class of SPATE. The prevalence of SPATEs genes in non-CD strains was 55% (10/18) for class-1 and 28% (5/18) for class-2. With respect to the association between SPATE classes and the most frequent genomic types found in CD strains (B2 and D), no significant differences were detected in the presence of class-1 SPATEs in B2 (67%, 8/12) or D (53%, 8/15). However, significant differences were observed in the presence of class-2 SPATES between genomic types B2 (75%, 9/12) and D (33%, 5/15). The *neuC* and Class-2 SPATEs showed different results between Spanish and Chilean CD strains (*p* \< 0.05) (Table [3](#T3){ref-type="table"}).

Genetic variations in *FimH*
----------------------------

Phylogenetic reconstruction of FimH, from 21 randomly selected CD *E. coli* isolates, indicated the presence of three major clades (Figure [2](#F2){ref-type="fig"}). Six out of 21 *E. coli* strains isolated from CD patients (5C08, 5I01, 10I01, CD1-a, CD2-a, and CD13-a) exhibited a FimH translated sequence identical to that of *E. coli* K12, whereas the remaining 15 showed the hot-spot mutation V27A. In this case, 9 amino-acid positions were affected by mutations (V27A, G66C, N70S, S78N, V163A, R166H, G194R, A202V, and Q269K) and generated 10 different allelic variants (Figure [2](#F2){ref-type="fig"}).

![**A phylogenetic tree based on FimH amino acid sequences of ***E. coli*** strains isolated from patients with CD**. This tree was constructed using 21 complete FimH sequences from *E. coli* isolates, the AIEC reference strain NRG857c, *E. coli* commensal HS, and *E. coli* K-12 (FimH consensus sequence from reference strain K12), using the nearest-neighbor joining method. The phylogenetic tree presents three main clades and shows 10 different allelic variants.](fmicb-08-00639-g0002){#F2}

Altogether, the results indicate that the *E. coli* strains obtained from CD patients from Chile and Spain were genetically different in nature and did not group according to their geographic origin. In both, Chile and Spain groups of strains, the prevalence of genes associated with iron uptake was high. Some of these strains harbored FimH variants, which is in agreement with previous studies (Iebba et al., [@B27]). In addition, we found at least one SPATE class was found in 65.6% of *E. coli* strains isolated from CD patients.

Discussion {#s4}
==========

*E. coli strains*, and in particular, the AIEC pathotype, have been identified by many authors as potentially implicated in the pathogenesis of CD (Darfeuille-Michaud et al., [@B14]; Boudeau et al., [@B7]; Glasser et al., [@B24]). The ability to adhere and invade epithelial cells, and survive intracellularly in macrophages characterizes this group of strains (Darfeuille-Michaud et al., [@B14]; Boudeau et al., [@B7]; Glasser et al., [@B24]; De la Fuente et al., [@B15]). Several virulence factors have been associated with these pathogenic properties in this pathotype (Conte et al., [@B12]; O\'Brien et al., [@B38]) however they are not exclusive to AIEC strains (Martinez-Medina and Garcia-Gil, [@B34]). Interestingly, production of type 1 fimbriae appears to correlate with adhesiveness of AIEC strains and certain FimH variants confer them a higher adhesion to intestinal epithelial cells (Dreux et al., [@B19]). In addition, mucosa-associated *E. coli* strains isolated from CD patients were very heterogeneous and the most of them belonged to B2 and D genomic types, according to previous investigations (Kotlowski et al., [@B30]; Martinez-Medina et al., [@B35]). The *E. coli* strains isolated from CD were significantly distributed among phylogenetic groups D (*p* = 0.031), A (*p* = 0.037), and B1 (*p* = 0.050) (Table [3](#T3){ref-type="table"}) when compared to non-CD strains. The phylogenetic group B2 was not significantly associated with any of the bacterial populations. The most common phylogenetic group among CD isolates was group D (47%) followed by groups B2 (37%), A (12.5%), and B1 (3.5%). Chilean and Spanish CD isolates were not significantly associated particularly with phylogenetic groups B2 (*p* = 0.058) or D (*p* = 0.369). In contrast, non-CD isolates were distributed among the following phylogenetic groups: A (36%), B1 (27%), and B2 and D, (18%). These results show significant differences among isolates of virulent strains associated with phylogenetic groups D and B2 from CD vs. non-CD (Table [3](#T3){ref-type="table"}). These results are similar to those reported by Nowrouzian et al. ([@B37]). It is possible that CD and non-CD subjects are transiently colonized by *E. coli* strains with different degrees virulence. However, it appears that those belonging the phylogenetic groups D and B2 are the most able of colonize and survive inside epithelial cells and macrophages in CD patients, particularly those harboring the *chuA* gene.

To date, all the features mentioned above have been studied in *E. coli* strains obtained from a particular geographic region. In this work however, we sought to investigate potential differences in mucosa-associated *E. coli* strains isolated from Chilean and Spanish patients with CD. To this end, we studied the genetic heterogeneity of these two *E. coli* populations, the presence of virulence factors known to be associated with CD *E. coli* and the occurrence of class-1 and class-2 SPATEs in these strains.

The clonal analyses of AIEC strains obtained from CD patients through PFGE showed a high degree of genetic variability, which is in agreement with the high variability of the distribution of virulence factors, and is similar to previous publications (Martinez-Medina et al., [@B35]; De la Fuente et al., [@B15]; O\'Brien et al., [@B38]). The B2 and D genomic groups were highly prevalent among strains from CD subjects, as has been shown in previous reports (Kotlowski et al., [@B30]; Martinez-Medina et al., [@B35]; De la Fuente et al., [@B15]). Remarkably, we found that strains from different countries did not group according to their origin.

The most distinctive feature of the AIEC strains studied was that all of them had virulence genes related to iron uptake (*fhuD, chuA*, and *irp2*), which is in agreement with previous reports demonstrating AIEC strain enrichment with siderophores (Dogan et al., [@B18]). If a strain harbored the *fhuD, chuA*, and *irp2* transporters together, a high association with CD was noted (Table [4](#T4){ref-type="table"}). The iron transporter gene *chuA* alone was also highly associated with CD (OR: 8.5, *p* = 0.001), as was the presence of the toxin gene *ratA* (OR: 7.7, *p* = 0.034).

The *fhuD* gene is common among pathogenic and non-pathogenic *E. coli* strains; however, *chuA* and *irp2* are less common among diarrheagenic and commensal *E. coli* strains. Nevertheless, both of these genes are present in ExPEC strains. The high prevalence of *fhuD, chuA*, and *irp2*, and its significance suggests that these three iron transporters or the presence of *chuA* alone may act as predictors of CD strains and AIEC isolated patients with CD. They may be relevant biological or diagnostic markers, which could be used to characterize and identify invasive strains isolated from CD patients. Another prevalent gene in the strains studied was *pduC*, which encodes proteins required for propanediol catabolism, was present in 50% of CD strains and in 66% of AIEC strains. *pduC* has been also described previously in the *S. enterica* serovar Thyphimurium (Bobik et al., [@B5]). The prevalence of *pduC* in AIEC strains in this study was similar to that reported by Dogan et al. who suggested that its presence in AIEC strains seems to be related to their persistence in macrophage cells (Dogan et al., [@B18]). However, *pduC* was not significantly associated with CD strains. The *neuC* gene is necessary for sialic acid synthesis, which is a carbohydrate monomer component of the K1 capsule, and is a virulence factor that is essential in *E. coli* strains causing meningitis in newborns (Vann et al., [@B43]). In addition, the K capsule contributes to intracellular replication of uropathogenic *E. coli* (UPEC) strains (Goller and Seed, [@B25]). *neuC* was present in 31% of CD strains and it is possible that NeuC plays a similar role in AIEC strains, contributing to its intracellular survival.

In agreement with previous studies, the gene encoding the FimH adhesin of type 1 fimbriae was present in almost all *E. coli* strains (De la Fuente et al., [@B15]). In AIEC strains this adhesin is considered a virulence factor and is responsible for mannose-dependent bacterial adherence and invasion of epithelial cells (Barnich et al., [@B3]; Brument et al., [@B8]; Dreux et al., [@B19]). FimH mediates the adhesion of AIEC strains to the apical surface of the ileal epithelium, specifically to the CEACAM6 protein, which is overexpressed in patients with CD (Barnich et al., [@B3]; Carvalho et al., [@B9]; Barnich and Darfeuille-Michaud, [@B4]). Different *fimH* allelic types occur in AIEC strains, which may increase adhesion to T84 cells and confer colonization advantages in the intestinal tract (Iebba et al., [@B27]; Dreux et al., [@B19]). Moreover, allelic replacement of the *fimH* gene in the AIEC LF82 genetic background by *fimH* from non-pathogenic K12 strains, significantly reduced bacterial colonization and colitis signs in CEABAC10 transgenic mice expressing human CEACAM6 (Dreux et al., [@B19]). Some of the mutations reported here, such as V27A, N70S, and S78N, have been previously reported in UPEC strains. These polymorphisms are considered to be potential patho-adaptations that may confer significant advantages in regards to bacterial epithelial colonization (Eris et al., [@B22]). Such patho-adaptative polymorphisms were also observed in *E. coli* strains obtained from pediatric patients with inflammatory bowel disease (IBD) (Iebba et al., [@B27]). V27A and G66C mutations in FimH were associated with CD, and G66S, N70S, and S78N were more prevalent in the B2 and D genomic groups (Iebba et al., [@B27]). However, Dreux et al. suggested that the V27A polymorphism was not associated with the AIEC pathotype (Dreux et al., [@B19]). The V27A mutation found in strains isolated from patients with IBD and CD was present in the isolates analyzed here. In our study, we confirmed the presence of several previously described mutations in AIEC strains (V27A, G66C, N70S, S78N, V163A, R166H, G194R, A202V, and Q269K) (Iebba et al., [@B27]; Dreux et al., [@B19]). However, the prevalence of V27A in the FimH gene in mucosa-associated *E. coli* isolated from Chilean and Spanish patients was 71%. Furthermore, the highly invasive AIEC strains, CD2-a and CD1-a (De la Fuente et al., [@B15]), lack any of the previously reported patho-adaptative polymorphisms. It is likely that adhesion and invasion mechanisms associated with these strains are mediated by other adhesins. Our results are consistent with previous report by Desilets et al. ([@B16]), who suggested that there is no strict association between the previously described polymorphisms of FimH in the AIEC pathotype and its superior adhesion and invasion ability (Desilets et al., [@B16]).

The prevalence of SPATE genes in mucosa-associated *E. coli* isolates was also analyzed. SPATE function is varied, they can have intracellular or extracellular protein substrates, and are involved in numerous biological functions, such as those implicated in cytoskeleton stability, autophagy or innate and adaptive immunity (Ruiz-Perez and Nataro, [@B39]). These proteins have evolved distinct functions that are adaptive to the particular niche occupied by the pathogen (Henderson and Nataro, [@B26]). We found that 65% of the CD and 73% of AIEC strain isolates presented at least one SPATE gene class. This prevalence is high, but not significantly higher than in the control group (61.1%). These results are similar to those reported by Souza et al., who did not find a significant difference in the presence of SPATEs between CD and control samples (De Souza et al., [@B17]).

Class-1 SPATE genes were present in 53.1% of CD strains. To date, there are no reports that associate the presence of class-1 SPATEs with CD. Yet, the cytotoxic activity and cellular damage associated with these proteins may promote the intestinal inflammation characteristic of CD. In this context, cytotoxic SPATEs have been found almost exclusively in microbial pathogens (*Shigella*, enteroagregative *E. coli* and enteroinvasive *E. coli*) that induce mucosal damage and inflammation (Boisen et al., [@B6]). Class-2 SPATE genes were present in 43% of CD isolates and 61.5% of AIEC strains. For most of the proteins of this class, little is known about their possible role in pathogenesis. However, most of the class-2 SPATEs studied to date display proteolytic activity on mucins (Ruiz-Perez and Nataro, [@B39]), which facilitates the interactions of the bacteria with the intestinal mucosa. Recently, these proteins have been reported to harbor lectin-like properties, conferring the capability of agglutination and adhesion to diverse white cells, as well as the ability to modulate the immune response at distinct levels, cleaving chemokines, complement proteins, adhesion proteins, and co-stimulatory molecules, all involved in malignancy and inflammatory processes (Ayala-Lujan et al., [@B2]), which may contribute to AIEC pathogenicity.

In conclusion, *E. coli* strains isolated from CD patients from Spain and Chile show a high degree of genetic variability. They also show significant variability in the virulence genes present, with the exception of genes involved in iron uptake and the *ratA* toxin gene, which were highly represented in CD strains and are likely to play a relevant role in AIEC pathogenesis. Furthermore, we did not observe an association between the FimH polymorphism and the adhesion and invasion ability of the strains studied. On the other hand, class-1 and -2 SPATE genes were not significantly more prevalent in CD strains or non-CD strains. This study highlights the potential of virulence genes present in CD strains to play a significant role in the pathogenesis of this disease. It is important to highlight that of all of the *E. coli* strains isolated from patients with CD, both in Chile and Spain, 40% (13/32) were identified as AIEC strains, whose classical characteristics are adhesion to and invasion of cells in culture and resistance to phagocytosis by macrophages.
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